Title 21Food and DrugsRelease 119-73

§360g–1 Agency documentation and review of significant decisions regarding devices

Title 21 › Chapter CHAPTER 9— - FEDERAL FOOD, DRUG, AND COSMETIC ACT › Subchapter SUBCHAPTER V— - DRUGS AND DEVICES › Part Part A— - Drugs and Devices › § 360g–1

Last updated Apr 6, 2026|Official source

Summary

The Secretary must give a clear, written summary of the science and reasons behind any major decision by the FDA’s Center for Devices and Radiological Health about reports under 21 U.S.C. 360(k), classification petitions under 21 U.S.C. 360c(f), applications under 21 U.S.C. 360e, or exemptions under 21 U.S.C. 360j(g). The summary must note important disagreements and how they were resolved, and must briefly say how the “least burdensome” rules under 21 U.S.C. 360c(i)(1)(D), 360c(a)(3)(D), and 360e(c)(5) were considered. If someone asks, the Secretary must give that summary to the person who wants to submit or already submitted the report or application. Any person can ask for a supervisory review of such a decision. The review goes to the next supervisor or higher. The person must ask within 30 days and say if they want an in-person meeting or a teleconference. If requested, the Secretary must set the meeting or call within 30 days and must issue a decision within 45 days of the request, or within 30 days after the meeting or call. These timing rules do not apply when the case is sent to experts outside the FDA.

Full Legal Text

Title 21, §360g–1

Food and Drugs — Source: USLM XML via OLRC

(a)(1)The Secretary shall provide a substantive summary of the scientific and regulatory rationale for any significant decision of the Center for Devices and Radiological Health regarding submission or review of a report under section 360(k) of this title, a petition for classification under section 360c(f) of this title, an application under section 360e of this title, or an application for an exemption under section 360j(g) of this title, including documentation of significant controversies or differences of opinion and the resolution of such controversies or differences of opinion.
(2)Upon request, the Secretary shall furnish such substantive summary to the person who is seeking to submit, or who has submitted, such report or application.
(3)The substantive summary required under this subsection shall include a brief statement regarding how the least burdensome requirements were considered and applied consistent with section 360c(i)(1)(D) of this title, section 360c(a)(3)(D) of this title, and section 360e(c)(5) of this title, as applicable.
(b)(1)Any person may request a supervisory review of the significant decision described in subsection (a)(1). Such review may be conducted at the next supervisory level or higher above the individual who made the significant decision.
(2)A person requesting a supervisory review under paragraph (1) shall submit such request to the Secretary not later than 30 days after such decision and shall indicate in the request whether such person seeks an in-person meeting or a teleconference review.
(3)(A)Except as provided in subparagraph (B), the Secretary shall schedule an in-person or teleconference review, if so requested, not later than 30 days after such request is made. The Secretary shall issue a decision to the person requesting a review under this subsection not later than 45 days after the request is made under paragraph (1), or, in the case of a person who requests an in-person meeting or teleconference, 30 days after such meeting or teleconference.
(B)Subparagraph (A) shall not apply in cases that are referred to experts outside of the Food and Drug Administration.

Legislative History

Notes & Related Subsidiaries

Editorial Notes

Amendments

2022—Subsec. (a)(1). Pub. L. 117–328 amended par. (1) generally. Prior to amendment, text read as follows: “The Secretary shall provide a substantive summary of the scientific and regulatory rationale for any significant decision of the Center for Devices and Radiological Health regarding submission or review of a report under section 360(k) of this title, an application under section 360e of this title, a request for designation under section 360e–3 of this title, or an application for an exemption under section 360j(g) of this title, including documentation of significant controversies or differences of opinion and the resolution of such controversies or differences of opinion.” 2016—Subsec. (a)(1). Pub. L. 114–255, § 3051(b), inserted “a request for designation under section 360e–3 of this title,” after “application under section 360e of this title,”. Subsec. (a)(3). Pub. L. 114–255, § 3058(c), added par. (3).

Reference

Citations & Metadata

Citation

21 U.S.C. § 360g–1

Title 21Food and Drugs

Last Updated

Apr 6, 2026

Release point: 119-73